QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-maintains-market-outperform-on-neuronetics-lowers-price-target-to-3

JMP Securities analyst David Turkaly maintains Neuronetics (NASDAQ:STIM) with a Market Outperform and lowers the price targe...

 canaccord-genuity-maintains-buy-on-neuronetics-lowers-price-target-to-3

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $...

 william-blair-downgrades-neuronetics-to-market-perform

William Blair analyst Margaret Kaczor downgrades Neuronetics (NASDAQ:STIM) from Outperform to Market Perform.

 noninvasive-treatment-provider-neuronetics-agrees-to-merge-with-canadian-firm-greenbrook-tms-reports-q2-earnings-and-guidance-below-expectations

Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expect...

 neuronetics-forecasts-q3-revenue-of-185m-195m-versus-consensus-of-20115m-with-2024-sales-of-78m-80m-compared-to-consensus-of-7915m

For the full year 2024, the Company expects total operating expenses to be between $78.0 million and $80.0 million.

 neuronetics-agreed-to-acquire-greenbrook-tms-in-an-all-stock-transaction

The transaction creates a vertically-integrated organization capable of providing access to mental health treatment with signif...

 neuronetics-announces-aetna-policy-update-expands-tms-availability-for-adolescents-with-depression

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

 william-blair-upgrades-neuronetics-to-outperform

William Blair analyst Margaret Kaczor upgrades Neuronetics (NASDAQ:STIM) from Market Perform to Outperform.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION